Etretinate is a second-generation retinoid that was used as an active pharmaceutical ingredient in medications for severe psoriasis. It was developed by Hoffmann–La Roche and approved by the FDA in 1986, but later withdrawn from several markets due to a high risk of birth defects.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 54350-48-0
Butyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
pharmaceutical intermediate
Butyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
pharmaceutical intermediate
Acitretin Impurity 10
pharmaceutical intermediate
(R)-Tetrahydropapaverine hydrochloride
pharmaceutical raw material
Phosphoric acid triethylene imide
pharmaceutical raw material
Theofibrate
pharmaceutical raw material
Aminolevulinic acid hydrochloride
pharmaceutical raw material
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
HQMNCQVAMBCHCO-DJRRULDNSA-N
CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C